Metraipolis › archive › dc_a8bfc883dd13

Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns — Europe PMC PMID:41321383

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41321383
DOI: 10.5599/admet.2956
License (as archived): solo-consultazione
Archived: 2026-11-09T08:44:30.538Z
SHA-256 of the archived text: b27caa122b1ba2544e33365e64f21daa6f903ae3e0ad534be2b6ad8f7916dbee
Stable URL of this page: https://metraipolis.com/documento/dc_a8bfc883dd13

How to cite

Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns — Europe PMC PMID:41321383 — Europe PMC (en), https://europepmc.org/article/MED/41321383 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a8bfc883dd13 (Metraipolis archive dc_a8bfc883dd13, sha256 b27caa122b1ba2544e33365e64f21daa6f903ae3e0ad534be2b6ad8f7916dbee)

BibTeX

@misc{dca8bfc883dd13,
  title = {Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns — Europe PMC PMID:41321383},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41321383},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a8bfc883dd13; sha256 b27caa122b1ba2544e33365e64f21daa6f903ae3e0ad534be2b6ad8f7916dbee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41321383. Agents can read the archived copy with the MCP tool read_document.